62 related articles for article (PubMed ID: 33992120)
21. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Peng X; Yu M; Chen J
J Int Med Res; 2020 Sep; 48(9):300060520950912. PubMed ID: 32878513
[TBL] [Abstract][Full Text] [Related]
24. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.
Phillips-Chavez C; Watson M; Coward J; Schloss J
Eur J Clin Pharmacol; 2020 Aug; 76(8):1059-1074. PubMed ID: 32440721
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
Matei D; Nephew KP
Cancer Res; 2020 Sep; 80(18):3775-3785. PubMed ID: 32381656
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
28. Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma.
Xu SF; Zheng Y; Zhang L; Wang P; Niu CM; Wu T; Tian Q; Yin XB; Shi SS; Zheng L; Gao LM
Mol Ther Nucleic Acids; 2019 Dec; 18():166-182. PubMed ID: 31557618
[TBL] [Abstract][Full Text] [Related]
29. Correlation of
Tang L; Wang P; Wang Q; Zhong L
Oncol Lett; 2019 Sep; 18(3):2813-2818. PubMed ID: 31402958
[TBL] [Abstract][Full Text] [Related]
30. The roles of DNA, RNA and histone methylation in ageing and cancer.
Michalak EM; Burr ML; Bannister AJ; Dawson MA
Nat Rev Mol Cell Biol; 2019 Oct; 20(10):573-589. PubMed ID: 31270442
[TBL] [Abstract][Full Text] [Related]
31. Epithelial ovarian cancer.
Lheureux S; Gourley C; Vergote I; Oza AM
Lancet; 2019 Mar; 393(10177):1240-1253. PubMed ID: 30910306
[TBL] [Abstract][Full Text] [Related]
32. Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?
Hentze JL; Høgdall CK; Høgdall EV
Mol Clin Oncol; 2019 Mar; 10(3):323-330. PubMed ID: 30847169
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: A meta-analysis.
Feng LY; Chen CX; Li L
Medicine (Baltimore); 2019 Feb; 98(8):e14588. PubMed ID: 30813180
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
36. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
37. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression.
Pan Z; Li L; Fang Q; Zhang Y; Hu X; Qian Y; Huang P
Cancer Cell Int; 2018; 18():214. PubMed ID: 30598639
[TBL] [Abstract][Full Text] [Related]
38. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and Treatment of Ovarian Cancer.
Orr B; Edwards RP
Hematol Oncol Clin North Am; 2018 Dec; 32(6):943-964. PubMed ID: 30390767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
